News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Talecris Biotherapeutics Study Demonstrates Aerosolized Prolastin(R) Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs



9/18/2007 11:47:33 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. (http://www.talecris.com) presented new data today at the 2007 Annual Congress of the European Respiratory Society (ERS) demonstrating that using the AKITA2® APIXNEB® system (Activaero Technologies) to inhale Prolastin® (Alpha-1 Proteinase Inhibitor [Human]) results in very high levels of drug deposited in the central and peripheral regions of the lungs. The clinical study data demonstrated that distribution in patients with alpha-1 antitrypsin (AAT) deficiency and cystic fibrosis who had moderate to severe lung function impairment was similar to levels achieved in healthy subjects.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES